Home › Funds › Lynx1 Capital Management LP › AGIO
Lynx1 Capital Management LP position in AGIO
AGIOS PHARMACEUTICALS INC · Health Care
Lynx1 Capital Management LP reported holding 3,408,937 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$126.5M, representing 14.62% of its reported portfolio and ranking #4 among its reported holdings. Lynx1 Capital Management LP has disclosed AGIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's AGIO position evolved
Lynx1 Capital Management LP first disclosed a stake in AGIO in Q4 2025 at 79,624 shares (US$2.2M). The position peaked in Q2 2026 at 3,408,937 shares, worth US$126.5M. Across 3 filings, Lynx1 Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,408,937 shares valued at US$126.5M — an increase of 797,369 shares quarter over quarter.. Notable position changes include a 3180% increase in Q1 2026 (shares rose 10% over the following quarter), a 31% increase in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 79.62K | $2.17M | New |
| Q1 2026 | 2.61M | $88.35M | Add |
| Q2 2026 | 3.41M | $126.51M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGIO and 13F data
AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$219.6M), ARMISTICE CAPITAL, LLC (US$89.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGIO
- Farallon Capital Management 5.92M sh · $219.59M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 5.92M sh · $219.59M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.40M sh · $89.06M · Q2 2026
- Erste Asset Management GmbH 2.15M sh · $81.97M · Q2 2026
- ADAR1 Capital Management, LLC 1.29M sh · $47.80M · Q2 2026
- Foresite Capital Management VI LLC 785.00K sh · $29.13M · Q2 2026
- Parkman Healthcare Partners LLC 669.05K sh · $24.83M · Q2 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held AGIO?
Lynx1 Capital Management LP has disclosed AGIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Lynx1 Capital Management LP's current position in AGIO?
As of Q2 2026, Lynx1 Capital Management LP holds 3.41M shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $126.51M, representing 14.62% of its reported portfolio and ranking #4.
Has Lynx1 Capital Management LP been buying or selling AGIO?
In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP increased its position in AGIO. The position peaked in Q2 2026 at 3.41M shares.
Which other funds hold AGIO?
Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., ARMISTICE CAPITAL, LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.